Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Hi C11
I'm not sure how much actual time there is to do the analysis but the scan measurements can be taken virtually as the data is produced. All the blood works for the trial are probably pushed through the labs in a few days.
I would think the first 10 - 12 patients scans and data will be completed this coming week or just after Easter Monday.
All of this is just logical thinking as we have no way to find out all the actual scan dates.
The main point is that Scancell 'should' have all the 16 week compiled data for those first 14 patients before they even leave for the USA.
Chester.
Hi JB
I totally agree with your post.
When I did the same exercise I guessed that for the data / figures to be released on the 21st Feb Scancell must have had the data from the 14th patient at least two weeks earlier. Ensuring that the data was accurate, checked and double checked before that RNS release.
So my take is that all the 16 week scans will be completed and verified much more quickly as it's just adding that final patient scan to the files already generated.
I would therefore expect Scancell to have all that data in hand just after the easter break, around the 14th April latest.
I'm convinced it will not be all last minute...
Chester.
Oh for the good days Ray.
Getting back home early on a Friday night to catch up on the inevitable heavy weight spats. When we had no trials going and any random theories could championed by someone from either side of the void.
Now all we have are facts and then the wait for the next set of facts. Its just not the same ...... so to ease the boredom, the old tried and trusted 'how are we going to keep the lights on' gambit, gets a dusting off and sent back out in new attire.
So many facts yet to arrive and maybe some juicy ones this month.
Chester......... : )
Being very pragmatic, I'm viewing April as a pivitol month, for three good reasons.
ISA's can be loaded up with cheaper shares due to the recent retrace. Thank you Ichor.
ModiFY trial to yield 16 week scan data.
LD to present new data at a very prestigious event.
It would be very comforting to see a positive RNS every week but in the real world one or two a month is about the norm.
I realise that the 18th could be a very slight improvement on the initial ModiFY RNS but it is also very possible that the data being shared that day will of the kind that moves the SP northwards and puts a smile on all our faces.
Chester.
Hi PaulBrains
Redmile will give all the guidance that our BOD need regarding finance. It is their £40million that's being spent on turning our science ideas into valuable technologies.
I'm sure Redmile will be very aware of the need to generate more capital to continue the ModiFY Trial, the iSCIB+ Trial, the 2024 Modi 2 Trial and the 2024 TCB Antibodies Trial, all announced by Scancell.
Given the ambition of Scancell to run 4 Trials next year you would expect the font of that funding to be fully understood and realised.
The AACR Presentation will set the tone for what is expected, trials wise, for the rest of 2023.
Another deal on GlyMabs would be nice.
We have three collaborations outstanding :
a Chinese BioTech (Dec 2019),
a USA based Clinical StagecAntibody Co. Possibly Seagen Inc. (Jan 2020), and
a Major European Pharma (Mar 2022).
Plus there are other possible routes to cash which we know about.
Chester.
Exactly.
At some point the ModiFY Trial will produce a set of results that will show if its a blockbuster technology or its a good technology that needs some more tweaks.
I'm hopeful that it will be the former.
On the day that we received such an RNS the number of shares you own will be far more valuable than any you have sold for a profit in the past.
It may happen in a 'utopian world' that the company is sold 'lock stock and barrel' at a very handsome price tag, if that happens there will be many saying 'if only I'd kept those shares'.
It won't be me.
Chester.
For a start Ichor dumping 3.5m shares at around 16p dragged the SP down and then the sentiment changed to negative.
I cannot see on what basis, if you are invested, would you be nervous. Those trading probably didn't do to well and now those that don't quite understand just how far the science has been validated are beginning to get jumpy.
The fact that all financial markets are somewhat nervous means that any non cash producing shares ( and especially on the Aim Market ) are seen as more risky.
Scancell is moving through the gears with their 4 technology platforms, 3 trials and one 'over the line' deal.
I'm content to see what comes out in the next 12 ( market open ) days and as Flakey says on the 6th April £20k of shares can be transfered to an ISA. At 15.5p that's around 120,000 non taxable shares.
For me I can only see the current status of the company as positive.
Please do your own research and if you do you may find that you agree with my positive stance.
Chester.
Morning C11
Agreed, I think there have been two occasions where you would normally expect a Proactive Investors type interview that have been passed up.
The GenMab License was an ideal opportunity and the Initial ModiFY Safety and Immunogenicity report especially the partial response and stable patient outcomes.
Chester.
Through their reluctance to do any one to one interviews or RNS news worthy items ( like the AACR presentation ) Scancell have shown a definite Strategy.
We can only conclude that everything is being kept under wraps and these are coordinated and deliberate decisions.
As we have discussed before, we are not party to all the discussions or interest being shown in our platforms by larger BioTech companies.
I'm hoping that this run up to the AACR attendance and presentation on the 18th April is when we begin to understand what is behind the current lack of PR.
Chester.
For info only, potential news horizon :
The GenMab License agreement reached 5 months yesterday, decision if they want to go into Phase 1 Trials must be close.
ModiFY Trial 7 months old this coming Friday.
New Chairman been in the job 2 months next Saturday.
SCOPE Trial was Expanded 10 months ago on the 15th April, Soon to progress to iSCIB+.
ModiFY Trial 16 week update report anytime from Mid April.
AACR Presentation by LD on the 18th April.
Potential News items :
Possible 2nd GlyMab Deal (USA Biotech)
Possible 1st AvidiMab Deal
Possible interest in Covidity (hopefully)
BionTech Deal for the supply the required ModiFY 'T' Cells
Modi 2 Being prepared to enter trials in 2024
TCB Antibodies being prepared for Trial in 2024
and lastly,
There is the potential that a new Senior Director could be appointed either to assist LD as a CSO or an Industry Expert in Sales and Marketing.
If that appointment does happen dependant on what that Senior position is we will have some insight into what the future direction of Scancell will be.
Just food for though.
Chester.
mRNA personalised cancer vaccines have a long road ahead. How are they harvesting the dna of the cancer cells. Is it via residue dna fragments in the blood, a biopsie or Circulating Cancer Cell capture.
The micro environment inside a tumour is always evolving and clusters with new mutations can brake free and seed new cancer sites that cannot be targeted by the original mRNA Vaccine.
So that trial of 350 patients will be a huge undertaking and our more straightforward DNA Vaccine trial will be concluded well before this mRNA trial is half way.
If it eventually works then fantastic but the cost per patient will be very high.
Chester.
The thing that makes Scancell more than just a 'maybe' is the foundations based on the results from the SCIB1 Ph1/2 trial.
Those results proved that Lindy and Co had the correct scientific knowledge and Immunbody was a perfectly good understanding of how to guide our immune system against cancer cells .
The ModiFY trial is now doing the same for their understanding of Moditopes power to engage CD4 Cytotoxic T Cells against solid tumours.
AvidiMab has been proven to work in the Covidity Trial and GenMab have put a potential value on one GlyMab target ( £600m if it reaches all three approvals ) .
16p a share is amazingly good value considering all what the above could and I stress could be worth.
Chester.
This one person's experience on Scancell's Trial must be considered as an outlier not only because the result is so surprising but that this is the only person who has openly shared their results so far.
When we first heard this information I got very excited and expected the same results from the other two patients in that Cohort. Then came the realisation that the other two had different cancer types and clearly not that one patients immune system.
It is without doubt an amazing outcome but must be treated, for now, as an outlier until the trial data shows otherwise.
Chester.
Hi Kashdog
Many research programmes and many bio-techs are looking at cancer solutions.
Scancell are taking on four very difficult to treat solid tumour types. That thins the field dramatically.
Even if we are only partly successful that will still be an amazing breakthrough with these particular nasty cancers.
Chin up, I do think we are backing the right company.
Chester.